Effects of repeated-dose isradipine on the abuse liability of cocaine

John D Roache, Bankole A. Johnson, Nassima Ait-Daoud, James B. Mauldin, Joe E. Thornton, Lynda T. Wells, William L. Murff

Research output: Contribution to journalArticle

13 Citations (Scopus)

Abstract

Despite preclinical studies suggesting that isradipine may antagonize the abuse liability of cocaine, pretreatment with sustained-release isradipine did not reduce euphoric mood in cocaine-using volunteers. This double-blind, within-subject, crossover laboratory study determined whether maximal dose-loading with isradipine could antagonize effects of cocaine in 12 cocaine-dependent research volunteers administered intravenous cocaine doses (0, 0.325, and 0.65 mg/kg) on different days after 5 days of treatment with isradipine or placebo. Isradipine dose was 30 mg sustained release nightly plus 15 mg immediate release 2 hr before cocaine infusion. Cocaine produced dose-related increases in cocaine's subjective effects and a behavioral measure of reinforcement. Isradipine enhanced, rather than antagonized, subjective effects, indicating that isradipine does not antagonize cocaine's abuse liability in dependent research volunteers.

Original languageEnglish (US)
Pages (from-to)319-326
Number of pages8
JournalExperimental and Clinical Psychopharmacology
Volume13
Issue number4
DOIs
StatePublished - Nov 2005

Fingerprint

Isradipine
Cocaine-Related Disorders
Cocaine
Volunteers
Research
Cross-Over Studies
Placebos

Keywords

  • Calcium channel antagonist
  • Cocaine
  • Drug abuse
  • Isradipine
  • Treatment

ASJC Scopus subject areas

  • Pharmacology
  • Experimental and Cognitive Psychology

Cite this

Roache, J. D., Johnson, B. A., Ait-Daoud, N., Mauldin, J. B., Thornton, J. E., Wells, L. T., & Murff, W. L. (2005). Effects of repeated-dose isradipine on the abuse liability of cocaine. Experimental and Clinical Psychopharmacology, 13(4), 319-326. https://doi.org/10.1037/1064-1297.13.4.319

Effects of repeated-dose isradipine on the abuse liability of cocaine. / Roache, John D; Johnson, Bankole A.; Ait-Daoud, Nassima; Mauldin, James B.; Thornton, Joe E.; Wells, Lynda T.; Murff, William L.

In: Experimental and Clinical Psychopharmacology, Vol. 13, No. 4, 11.2005, p. 319-326.

Research output: Contribution to journalArticle

Roache, JD, Johnson, BA, Ait-Daoud, N, Mauldin, JB, Thornton, JE, Wells, LT & Murff, WL 2005, 'Effects of repeated-dose isradipine on the abuse liability of cocaine', Experimental and Clinical Psychopharmacology, vol. 13, no. 4, pp. 319-326. https://doi.org/10.1037/1064-1297.13.4.319
Roache, John D ; Johnson, Bankole A. ; Ait-Daoud, Nassima ; Mauldin, James B. ; Thornton, Joe E. ; Wells, Lynda T. ; Murff, William L. / Effects of repeated-dose isradipine on the abuse liability of cocaine. In: Experimental and Clinical Psychopharmacology. 2005 ; Vol. 13, No. 4. pp. 319-326.
@article{113da177ba60457ba452559d85ac0af2,
title = "Effects of repeated-dose isradipine on the abuse liability of cocaine",
abstract = "Despite preclinical studies suggesting that isradipine may antagonize the abuse liability of cocaine, pretreatment with sustained-release isradipine did not reduce euphoric mood in cocaine-using volunteers. This double-blind, within-subject, crossover laboratory study determined whether maximal dose-loading with isradipine could antagonize effects of cocaine in 12 cocaine-dependent research volunteers administered intravenous cocaine doses (0, 0.325, and 0.65 mg/kg) on different days after 5 days of treatment with isradipine or placebo. Isradipine dose was 30 mg sustained release nightly plus 15 mg immediate release 2 hr before cocaine infusion. Cocaine produced dose-related increases in cocaine's subjective effects and a behavioral measure of reinforcement. Isradipine enhanced, rather than antagonized, subjective effects, indicating that isradipine does not antagonize cocaine's abuse liability in dependent research volunteers.",
keywords = "Calcium channel antagonist, Cocaine, Drug abuse, Isradipine, Treatment",
author = "Roache, {John D} and Johnson, {Bankole A.} and Nassima Ait-Daoud and Mauldin, {James B.} and Thornton, {Joe E.} and Wells, {Lynda T.} and Murff, {William L.}",
year = "2005",
month = "11",
doi = "10.1037/1064-1297.13.4.319",
language = "English (US)",
volume = "13",
pages = "319--326",
journal = "Experimental and Clinical Psychopharmacology",
issn = "1064-1297",
publisher = "American Psychological Association Inc.",
number = "4",

}

TY - JOUR

T1 - Effects of repeated-dose isradipine on the abuse liability of cocaine

AU - Roache, John D

AU - Johnson, Bankole A.

AU - Ait-Daoud, Nassima

AU - Mauldin, James B.

AU - Thornton, Joe E.

AU - Wells, Lynda T.

AU - Murff, William L.

PY - 2005/11

Y1 - 2005/11

N2 - Despite preclinical studies suggesting that isradipine may antagonize the abuse liability of cocaine, pretreatment with sustained-release isradipine did not reduce euphoric mood in cocaine-using volunteers. This double-blind, within-subject, crossover laboratory study determined whether maximal dose-loading with isradipine could antagonize effects of cocaine in 12 cocaine-dependent research volunteers administered intravenous cocaine doses (0, 0.325, and 0.65 mg/kg) on different days after 5 days of treatment with isradipine or placebo. Isradipine dose was 30 mg sustained release nightly plus 15 mg immediate release 2 hr before cocaine infusion. Cocaine produced dose-related increases in cocaine's subjective effects and a behavioral measure of reinforcement. Isradipine enhanced, rather than antagonized, subjective effects, indicating that isradipine does not antagonize cocaine's abuse liability in dependent research volunteers.

AB - Despite preclinical studies suggesting that isradipine may antagonize the abuse liability of cocaine, pretreatment with sustained-release isradipine did not reduce euphoric mood in cocaine-using volunteers. This double-blind, within-subject, crossover laboratory study determined whether maximal dose-loading with isradipine could antagonize effects of cocaine in 12 cocaine-dependent research volunteers administered intravenous cocaine doses (0, 0.325, and 0.65 mg/kg) on different days after 5 days of treatment with isradipine or placebo. Isradipine dose was 30 mg sustained release nightly plus 15 mg immediate release 2 hr before cocaine infusion. Cocaine produced dose-related increases in cocaine's subjective effects and a behavioral measure of reinforcement. Isradipine enhanced, rather than antagonized, subjective effects, indicating that isradipine does not antagonize cocaine's abuse liability in dependent research volunteers.

KW - Calcium channel antagonist

KW - Cocaine

KW - Drug abuse

KW - Isradipine

KW - Treatment

UR - http://www.scopus.com/inward/record.url?scp=29444446425&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=29444446425&partnerID=8YFLogxK

U2 - 10.1037/1064-1297.13.4.319

DO - 10.1037/1064-1297.13.4.319

M3 - Article

C2 - 16366762

AN - SCOPUS:29444446425

VL - 13

SP - 319

EP - 326

JO - Experimental and Clinical Psychopharmacology

JF - Experimental and Clinical Psychopharmacology

SN - 1064-1297

IS - 4

ER -